Skip to main content
CG Oncology, Inc. logo

CG Oncology, Inc. — Investor Relations & Filings

Ticker · CGON ISIN · US1569441009 US Manufacturing
Open in API
Filings indexed 174 across all filing types
Latest filing 2026-06-08 Declaration of Voting R…
Country US United States of America
Listing US CGON

About CG Oncology, Inc.

https://www.cgoncology.com/

CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing bladder-sparing therapeutics for patients with urologic cancers, particularly non-muscle invasive bladder cancer (NMIBC). The company's lead product candidate is cretostimogene grenadenorepvec, an investigational, intravesically delivered oncolytic immunotherapy. This therapy is designed with a dual mechanism of action to selectively replicate within and destroy cancer cells while stimulating a systemic anti-tumor immune response. The primary goal is to provide an effective treatment that preserves the bladder and improves the quality of life for patients.

Recent filings

Filing Released Lang Actions
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 96% confidence The document is a Form 8-K current report disclosing the final voting results for proposals at the company’s 2026 Annual Meeting of Stockholders, including election of directors and advisory votes. This matches the definition for Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-06-08 English
8-K
Board/Management Information Classification · 85% confidence The document is a Form 8-K current report filed with the SEC, specifically detailing the departure of the President & COO and the appointment of a new President. This is a clear announcement of changes in senior management, matching the 'Board/Management Information' category.
2026-05-26 English
8-K - CG Oncology, Inc. (0001991792) (Filer)
Report Publication Announcement Classification · 85% confidence The document is a Form 8-K “Current Report” that merely announces the company’s press release of quarterly results (Item 2.02) and states that the release is attached as Exhibit 99.1. It contains no substantive financial data itself and is under 5,000 characters. Per the “menu vs. meal” rule, this is an announcement that a report is attached, not the report itself, so it should be classified as a Report Publication Announcement.
2026-05-08 English
ARS - CG Oncology, Inc. (0001991792) (Filer)
Annual Report
2026-04-24 English
8-K - CG Oncology, Inc. (0001991792) (Filer)
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details the appointment of a new Chief Financial Officer, including biographical information, terms of employment, and severance provisions. This fits the category of announcements related to changes in the company's board of directors or senior management. There are no financial statements or detailed financial performance data present, so it is not an Annual Report or Interim Report. The document is not a proxy statement, earnings release, or any other category. Therefore, the appropriate classification is Board/Management Information (MANG). The document length and detail support a high confidence in this classification.
2026-04-13 English
SCHEDULE 13G/A - CG Oncology, Inc. (0001991792) (Subject)
Major Shareholding Notification
2026-03-26 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.